Search results: (10000)
News Position of Levodropropizine in Cough Therapy
An international group of specialists focused in 2016–2017 on a detailed evaluation of current options for cough therapy. The authors based their analysis on individually prepared reviews using Medline and Embase databases, and they presented their work's results last year in the journal Pulmonary Pharmacology & Therapeutics.
News Webinar SGLT2i in ESC HF Guidelines vs. Real Practice
Dear Doctor,
Boehringer Ingelheim, in collaboration with the 2nd Department of Internal Medicine - Department of Cardiology and Angiology,
General University Hospital and 1st Faculty of Medicine, Charles University, cordially invites you to an online discussion to be held on Tuesday, November 23, 2021, from 5:00 PM to 6:30 PM.
More information can be found in the attached invitation below.
News Erlotinib in Conditions of Routine Clinical Practice
The patient population in clinical trials is always somewhat selected. Only a well-conducted analysis of real-world clinical practice data can provide a clearer picture of the efficacy and safety of a drug. Therefore, we are currently witnessing a significant development in this type of clinical research, for example, in the form of nationwide cohort studies. How did erlotinib perform in one of them for the treatment of non-small cell lung cancer?
News What Are the Impacts of Not Administering Extended VTE Prophylaxis in Oncology Patients After GIT Surgeries?
In a freshly published retrospective study, experts from the University of Arkansas investigated how well the professional recommendation that cancer patients undergo extended venous thromboembolism (VTE) prophylaxis after major gastrointestinal (GI) surgeries is being followed and what impact this has in real practice.
News Quality of Life in Patients with mCRC Treated with mFOLFOXIRI and Panitumumab
At the congress of the European Society for Medical Oncology (ESMO) in September 2019, the results of the VOLFI study were presented, which also monitored the quality of life in patients with primarily unresectable wild-type (wt-RAS) metastatic colorectal cancer (mCRC) with an ECOG performance status of 0–1.
News FOLFOXIRI and Panitumumab in mCRC Treatment – Improvement in Treatment Response and Metastasis Resectability
For patients with metastatic colorectal cancer (mCRC) who are able to undergo intensive treatment, the FOLFOX (5-fluorouracil/leucovorin, oxaliplatin) or FOLFIRI (5-fluorouracil/leucovorin, irinotecan) regimens combined with monoclonal antibodies represent the standard first-line treatment. The FOLFOXIRI regimen, which is another option, was developed to further enhance the efficacy of chemotherapy. The German oncologists' VOLFI study investigated the effectiveness of combining targeted therapy and triplet chemotherapy compared to chemotherapy alone in previously untreated patients with mCRC without RAS oncogene mutation.
News Prevalence of Metabolic Syndrome During 1 Year After the First Episode of Psychosis
Portuguese authors elucidated the high prevalence of metabolic syndrome and adverse metabolic parameters in individuals with the first episode of psychosis. Moreover, it significantly increased during 1 year after this episode.
News Documented Cardiovascular Benefit of Empagliflozin in New American Diabetes Treatment Guidelines
Two leading overseas medical professional societies, the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE), released new recommendations for diabetes treatment in December 2016. They include information on the reduction of cardiovascular mortality in diabetics treated with empagliflozin (Jardiance).
News Meta-analysis of Efficacy and Safety of Third-Generation Antiseizure Medications in Adjunctive Treatment of Focal Seizures in Adults with Epilepsy
Epilepsy treatment is primarily symptomatic, aimed at reducing seizure frequency. However, more than 50% of patients do not achieve seizure freedom with monotherapy. Below we summarize the results of a meta-analysis comparing the efficacy and safety of third-generation antiseizure medications in the treatment of focal seizures in adults with epilepsy.
News Alpha-1-Antitrypsin Deficiency and Its Association with Atopy in Asthmatics
Literature mentions the coincidence of asthma and alpha-1-antitrypsin deficiency, which is caused by a mutation in the SERPINA1 gene. The aim of the study presented below was to determine whether the clinical symptoms of asthma differ between patients with and without this mutation.
News Current Status in the Issue of Alpha-1-Antitrypsin Deficiency
Material by Italian and Swiss authors published in the European Respiratory Review details current insights into alpha-1-antitrypsin (AAT) deficiency and the possibilities for its diagnosis and treatment. We provide a summary of the main points, including the specific option of augmentation therapy with exogenous AAT.
News Urgent Administration of Romiplostim in Life-Threatening Bleeding Associated with ITP
Recommendations for the care of acute, especially major bleeding in individuals with severe immune thrombocytopenia (ITP) are not entirely clear. Various methods (steroid boluses, intravenous immunoglobulins, platelet transfusions, etc.) can be used to quickly increase platelet count, but the response may not always be straightforward. Recently, reports have been published regarding the use of thrombopoietin receptor agonists (TPO-RAs) specifically aimed at rapidly increasing platelet count. The use of romiplostim in patients with ITP and intracranial hemorrhage is illustrated by the following case studies.
News Hereditary Angioedema as a Clinical Picture of Excessive Activation of the Kinin Cascade – Case Report
Painful and potentially life-threatening swellings are characteristic of hereditary angioedema (HAE), a rare genetically determined disease. Dutch authors present in a recently published review the case report of a young woman with a life-threatening laryngeal swelling.
News Comparison of the Efficacy of Tofacitinib and Vedolizumab in the Treatment of Ulcerative Colitis After Anti-TNF Therapy Failure
Therapeutic options for ulcerative colitis resistant to anti-TNF-α antibody treatment are available, but there were no studies comparing the selective immunosuppressants tofacitinib and vedolizumab in this patient population. The aim of this comparison was a multicenter French study, the first results of which were presented at the 17th ECCO Congress 2022.
News Epidemiology, Pathophysiology, Diagnosis, and Treatment of Heart Failure in Patients with Diabetes
The proven benefit of one class of antidiabetic drugs – sodium-glucose cotransporter 2 inhibitors (SGLT2i; gliflozins) – in treating heart failure irrespective of diabetes presence, and their inclusion in therapeutic recommendations for heart failure with reduced ejection fraction of the left ventricle, brings to light unresolved questions regarding the link between diabetes and heart failure. A recently published article summarizes the current knowledge on the epidemiology and pathophysiological connection of these two diseases, as well as the current recommended diagnosis and treatment.
News Emicizumab Changes the Lifestyle of Patients with Hemophilia A
At the World Federation of Hemophilia (WFH) meeting, data were presented regarding the impact of emicizumab on the lifestyle of people with hemophilia A.
News Interactive Case Study: Treatment of Neuropathic Pain in a Patient with Neurodegenerative Disease
We offer a brief case study of a polymorbid patient suffering from chronic pain, spasticity, and sleep disturbances, among other issues. Medical cannabis was advantageously introduced, helping to alleviate several symptoms. You can interactively explore how you would proceed in this case.
News Evaluation of the m7-FLIPI score in patients with follicular lymphoma revealed a promising predictive biomarker for determining suitable chemotherapy
The authors of a study presented at the December congress of the American Society of Hematology (ASH) in Orlando introduced a new prognostic tool, m7-FLIPI, for determining the risk level of patients with follicular lymphoma (FL). They tested its utility using samples from the GALLIUM clinical trial and, during the analysis, discovered a promising biomarker that could help in selecting the primary chemotherapy for FL patients.
News Association Between Sartan Therapy and Lower Incidence of Epilepsy in Hypertensive Patients?
Arterial hypertension (AH) is one of the non-cerebral comorbidities of epilepsy, with the renin-angiotensin system possibly being the central mediator of the connection between these diseases. The German study cited below therefore examined whether therapy with AT1 receptor blockers for angiotensin II (ARBs, i.e., sartans) reduces the risk of epilepsy in patients with AH as suggested by animal studies.
News Treatment of HFrEF with Sacubitril/Valsartan Does Not Have to Be the ‘Last Resort’
The TRANSITION study has provided evidence on the safety and efficacy of administering sacubitril/valsartan to patients after acute decompensation of chronic heart failure with reduced ejection fraction of the left ventricle (HFrEF). A recent sub-analysis of its results suggested that not only patients with a long-known diagnosis but also those with newly diagnosed HFrEF could benefit from the treatment if the possibility of its prescription in this indication arises.
News Recent Advances in Physiotherapy for Hemophiliacs
Physiotherapy specifically focuses on movement and the movement potential of the individual, with the purpose of restoring or maintaining maximum mobility and functional abilities throughout life. Numerous experiences have shown that physiotherapeutic procedures hold a key position for patients with hemophilia.
News Good Efficacy of Brigatinib After Failure of 2nd Generation ALK Inhibitors
Brigatinib is commonly used in the treatment of ALK-positive non-small cell lung cancer (NSCLC) in the 2nd line after progression on a 1st-generation ALK inhibitor, crizotinib. American scientists in a phase II study focused on the efficacy of brigatinib in the treatment of patients with advanced NSCLC who had progressed on 2nd-generation ALK inhibitors.
News Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients with Hypercholesterolemia – Meta-Analysis of 35 Randomized Controlled Trials
The authors from several American institutions examined the efficacy and safety of two proprotein convertase subtilisin/kexin type 9 (PCSK9i) inhibitors, alirocumab and evolocumab, in their work. They conducted a systematic meta-analysis of randomized controlled clinical trials comparing the administration of these two PCSK9i with standard treatment.
News Perioperative Management of Bleeding in Patients with von Willebrand Disease Using Coagulation Factors
Von Willebrand disease is one of the most common congenital bleeding disorders. It is a heterogeneous group of diseases with varying severity of clinical manifestations. Some patients require pharmacological prevention or treatment of bleeding as part of perioperative care. The administration of concentrates containing coagulation factors is currently the gold standard for certain types of von Willebrand disease.
News If Suicides Were COVID-19... or Why We Still Overlook a Significant Cause of Premature Deaths?
More than a year since the start of the pandemic, the SARS-CoV-2 coronavirus has claimed 2.8 million lives globally, with 127 million recorded cases of COVID-19 (as of March 29, 2021). According to World Health Organization (WHO) data, there are 800,000 suicides annually, with suicide attempts being up to 20 times more frequent, totaling over 16 million. Given our current focus on physical health, are we overlooking the extent and importance of mental health issues in the population? This question has been raised by several experts from different countries in their submission to the February issue of The Journal of Clinical Psychiatry.